<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p158" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_158{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_158{left:306px;bottom:30px;}
#t3_158{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_158{left:346px;bottom:30px;}
#t5_158{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_158{left:517px;bottom:30px;}
#t7_158{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_158{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_158{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_158{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_158{left:35px;bottom:777px;letter-spacing:0.07px;word-spacing:-0.13px;}
#tc_158{left:35px;bottom:754px;letter-spacing:0.15px;word-spacing:-0.41px;}
#td_158{left:35px;bottom:731px;letter-spacing:0.34px;word-spacing:-1.38px;}
#te_158{left:90px;bottom:731px;}
#tf_158{left:106px;bottom:731px;letter-spacing:0.25px;word-spacing:-0.06px;}
#tg_158{left:35px;bottom:707px;letter-spacing:0.16px;word-spacing:0.02px;}
#th_158{left:35px;bottom:684px;letter-spacing:0.11px;word-spacing:-1.06px;}
#ti_158{left:35px;bottom:661px;letter-spacing:0.17px;word-spacing:0.01px;}
#tj_158{left:35px;bottom:638px;letter-spacing:0.01px;word-spacing:-0.09px;}
#tk_158{left:35px;bottom:614px;letter-spacing:0.2px;word-spacing:-0.01px;}
#tl_158{left:35px;bottom:591px;letter-spacing:0.09px;word-spacing:-0.99px;}
#tm_158{left:35px;bottom:568px;letter-spacing:0.13px;word-spacing:-0.93px;}
#tn_158{left:475px;bottom:576px;letter-spacing:-0.01px;}
#to_158{left:497px;bottom:568px;letter-spacing:-0.41px;}
#tp_158{left:35px;bottom:545px;letter-spacing:0.19px;word-spacing:-0.01px;}
#tq_158{left:35px;bottom:506px;letter-spacing:0.14px;word-spacing:-0.09px;}
#tr_158{left:35px;bottom:482px;letter-spacing:0.1px;word-spacing:0.08px;}
#ts_158{left:35px;bottom:459px;letter-spacing:0.11px;word-spacing:0.07px;}
#tt_158{left:35px;bottom:436px;letter-spacing:0.24px;}
#tu_158{left:117px;bottom:444px;letter-spacing:-0.11px;}
#tv_158{left:222px;bottom:436px;letter-spacing:0.09px;word-spacing:-0.52px;}
#tw_158{left:35px;bottom:413px;letter-spacing:0.11px;word-spacing:-0.24px;}
#tx_158{left:35px;bottom:390px;letter-spacing:0.09px;word-spacing:-0.77px;}
#ty_158{left:35px;bottom:366px;letter-spacing:0.07px;word-spacing:-1.11px;}
#tz_158{left:315px;bottom:366px;}
#t10_158{left:330px;bottom:366px;letter-spacing:0.06px;word-spacing:-0.08px;}
#t11_158{left:35px;bottom:343px;letter-spacing:0.1px;word-spacing:0.09px;}
#t12_158{left:529px;bottom:351px;letter-spacing:-0.01px;}
#t13_158{left:35px;bottom:320px;letter-spacing:0.15px;word-spacing:0.04px;}
#t14_158{left:35px;bottom:297px;letter-spacing:0.11px;word-spacing:0.08px;}
#t15_158{left:35px;bottom:273px;letter-spacing:0.19px;}
#t16_158{left:35px;bottom:250px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t17_158{left:169px;bottom:250px;}
#t18_158{left:185px;bottom:250px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t19_158{left:235px;bottom:258px;letter-spacing:-0.01px;}
#t1a_158{left:258px;bottom:250px;letter-spacing:0.24px;word-spacing:-0.05px;}
#t1b_158{left:35px;bottom:227px;letter-spacing:0.01px;word-spacing:-0.23px;}
#t1c_158{left:35px;bottom:204px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1d_158{left:35px;bottom:181px;letter-spacing:-0.06px;word-spacing:0.24px;}
#t1e_158{left:314px;bottom:188px;letter-spacing:-0.01px;}
#t1f_158{left:337px;bottom:181px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1g_158{left:35px;bottom:157px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1h_158{left:35px;bottom:134px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1i_158{left:35px;bottom:111px;letter-spacing:0.16px;}
#t1j_158{left:76px;bottom:118px;letter-spacing:-0.01px;}
#t1k_158{left:99px;bottom:111px;letter-spacing:0.01px;word-spacing:0.18px;}
#t1l_158{left:35px;bottom:88px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1m_158{left:35px;bottom:64px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1n_158{left:618px;bottom:777px;letter-spacing:0.16px;word-spacing:0.02px;}
#t1o_158{left:618px;bottom:754px;word-spacing:0.19px;}
#t1p_158{left:763px;bottom:761px;letter-spacing:0.1px;}
#t1q_158{left:618px;bottom:712px;letter-spacing:0.27px;word-spacing:-0.08px;}
#t1r_158{left:618px;bottom:689px;letter-spacing:0.06px;word-spacing:-0.99px;}
#t1s_158{left:618px;bottom:666px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1t_158{left:929px;bottom:673px;}
#t1u_158{left:974px;bottom:666px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1v_158{left:618px;bottom:643px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1w_158{left:618px;bottom:619px;letter-spacing:-0.04px;word-spacing:0.23px;}
#t1x_158{left:1087px;bottom:627px;}
#t1y_158{left:618px;bottom:596px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1z_158{left:618px;bottom:573px;letter-spacing:0.19px;}
#t20_158{left:618px;bottom:550px;letter-spacing:0.32px;word-spacing:-0.14px;}
#t21_158{left:862px;bottom:557px;letter-spacing:0.12px;}
#t22_158{left:929px;bottom:550px;letter-spacing:0.07px;word-spacing:0.12px;}
#t23_158{left:618px;bottom:526px;letter-spacing:0.15px;word-spacing:-0.97px;}
#t24_158{left:618px;bottom:503px;letter-spacing:0.12px;word-spacing:0.06px;}
#t25_158{left:618px;bottom:463px;letter-spacing:0.12px;word-spacing:-0.16px;}
#t26_158{left:618px;bottom:440px;letter-spacing:0.04px;word-spacing:0.14px;}
#t27_158{left:618px;bottom:416px;word-spacing:0.18px;}
#t28_158{left:618px;bottom:393px;letter-spacing:0.06px;word-spacing:-0.97px;}
#t29_158{left:618px;bottom:370px;letter-spacing:-0.05px;word-spacing:-0.18px;}
#t2a_158{left:618px;bottom:347px;letter-spacing:0.15px;word-spacing:-0.74px;}
#t2b_158{left:1084px;bottom:354px;letter-spacing:-0.01px;}
#t2c_158{left:1107px;bottom:347px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2d_158{left:618px;bottom:324px;letter-spacing:0.16px;word-spacing:-0.09px;}
#t2e_158{left:618px;bottom:300px;letter-spacing:0.18px;word-spacing:-0.73px;}
#t2f_158{left:1025px;bottom:308px;letter-spacing:-0.01px;}
#t2g_158{left:1049px;bottom:300px;letter-spacing:0.22px;word-spacing:-0.04px;}
#t2h_158{left:618px;bottom:277px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2i_158{left:618px;bottom:254px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2j_158{left:618px;bottom:215px;letter-spacing:0.18px;word-spacing:0.01px;}
#t2k_158{left:618px;bottom:192px;letter-spacing:0.11px;word-spacing:-0.08px;}
#t2l_158{left:618px;bottom:168px;letter-spacing:0.01px;word-spacing:0.17px;}
#t2m_158{left:763px;bottom:176px;letter-spacing:0.1px;}
#t2n_158{left:874px;bottom:168px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t2o_158{left:618px;bottom:145px;letter-spacing:0.09px;word-spacing:-0.46px;}
#t2p_158{left:618px;bottom:122px;letter-spacing:0.13px;word-spacing:-1.04px;}
#t2q_158{left:1155px;bottom:129px;letter-spacing:-0.01px;}
#t2r_158{left:618px;bottom:99px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t2s_158{left:1071px;bottom:106px;letter-spacing:-0.01px;}
#t2t_158{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_158{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_158{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_158{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_158{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_158{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_158{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_158{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_158{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts158" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg158Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg158" style="-webkit-user-select: none;"><object width="1210" height="935" data="158/158.svg" type="image/svg+xml" id="pdf158" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_158" class="t s0_158">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_158" class="t s1_158">© </span>
<span id="t3_158" class="t s0_158">(NCCN </span>
<span id="t4_158" class="t s1_158">© </span>
<span id="t5_158" class="t s0_158">), All rights reserved. NCCN Guidelines </span>
<span id="t6_158" class="t s1_158">® </span>
<span id="t7_158" class="t s0_158">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_158" class="t s2_158">NCCN Guidelines Version 4.2024 </span>
<span id="t9_158" class="t s2_158">Head and Neck Cancers </span>
<span id="ta_158" class="t s3_158">MS-17 </span>
<span id="tb_158" class="t s4_158">(LENT-SOMA scale) xerostomia 2 years after treatment was seen in 83% </span>
<span id="tc_158" class="t s4_158">of patients receiving conventional RT versus 29% of patients in the IMRT </span>
<span id="td_158" class="t s4_158">group (</span><span id="te_158" class="t s5_158">P </span><span id="tf_158" class="t s4_158">&lt; .0001). No differences were seen in the rates of locoregional </span>
<span id="tg_158" class="t s4_158">control or survival. A fourth trial, GORTEC 2004-01, showed that dose- </span>
<span id="th_158" class="t s4_158">escalated IMRT (75 Gy in 35 fractions followed by a sequential boost of 25 </span>
<span id="ti_158" class="t s4_158">Gy in 10 fractions), delivered concurrently with cisplatin, reduced </span>
<span id="tj_158" class="t s4_158">xerostomia in patients with locally advanced SCCHN, compared to 3D-RT </span>
<span id="tk_158" class="t s4_158">(70 Gy in 35 fractions followed by a sequential boost of 20 Gy in 10 </span>
<span id="tl_158" class="t s4_158">fractions) delivered concurrently with cisplatin (23% vs. 63%, respectively, </span>
<span id="tm_158" class="t s4_158">after 1 year, and 11% vs. 45%, respectively, after 3 years). </span>
<span id="tn_158" class="t s6_158">216 </span>
<span id="to_158" class="t s4_158">Locoregional </span>
<span id="tp_158" class="t s4_158">control did not significantly differ between the two study arms. </span>
<span id="tq_158" class="t s4_158">IMRT likely reduces other long-term toxicities due to decreased radiation </span>
<span id="tr_158" class="t s4_158">doses to structures such as pharyngeal constrictors, larynx, temporal </span>
<span id="ts_158" class="t s4_158">lobes, mandible, auditory structures (including cochlea), and optic </span>
<span id="tt_158" class="t s4_158">structures. </span>
<span id="tu_158" class="t s6_158">155,192,212,217-222 </span>
<span id="tv_158" class="t s4_158">For instance, in a phase III RCT from the UK and </span>
<span id="tw_158" class="t s4_158">Ireland, a dysphagia-optimized IMRT intervention in which the constrictor </span>
<span id="tx_158" class="t s4_158">muscles of the pharynx were spared improved swallowing outcomes at 12 </span>
<span id="ty_158" class="t s4_158">months compared to standard IMRT ( </span><span id="tz_158" class="t s5_158">P </span><span id="t10_158" class="t s4_158">= .037) in patients with early stage </span>
<span id="t11_158" class="t s4_158">and locally advanced cancers of the oropharynx or hypopharynx. </span>
<span id="t12_158" class="t s6_158">223 </span>
<span id="t13_158" class="t s4_158">Retrospective analyses including 2993 patients who received RT for </span>
<span id="t14_158" class="t s4_158">treatment of H&amp;N cancer showed that patients who received IMRT had a </span>
<span id="t15_158" class="t s4_158">shorter duration of feeding tube placement, compared to those who </span>
<span id="t16_158" class="t s4_158">received 3D-RT (</span><span id="t17_158" class="t s5_158">P </span><span id="t18_158" class="t s4_158">= .03). </span>
<span id="t19_158" class="t s6_158">224 </span>
<span id="t1a_158" class="t s4_158">There are numerous other specific </span>
<span id="t1b_158" class="t s4_158">advantages of IMRT that apply to challenging anatomical situations. IMRT </span>
<span id="t1c_158" class="t s4_158">is particularly useful in avoiding excess radiation of the optic pathway in </span>
<span id="t1d_158" class="t s4_158">patients with sinonasal malignancies. </span>
<span id="t1e_158" class="t s6_158">217 </span>
<span id="t1f_158" class="t s4_158">However, the randomized phase </span>
<span id="t1g_158" class="t s4_158">III COSTAR trial did not show that cochlear-sparing IMRT significantly </span>
<span id="t1h_158" class="t s4_158">reduced hearing loss in patients with parotid tumors, compared to 3D- </span>
<span id="t1i_158" class="t s4_158">CRT. </span>
<span id="t1j_158" class="t s6_158">222 </span>
<span id="t1k_158" class="t s4_158">One caveat is that additional care must be taken when using </span>
<span id="t1l_158" class="t s4_158">IMRT as it can create unanticipated toxicities to organs unexpectedly </span>
<span id="t1m_158" class="t s4_158">radiated in the beam path; a careful and informed examination of all </span>
<span id="t1n_158" class="t s4_158">organs potentially affected by these novel distributions of the radiation </span>
<span id="t1o_158" class="t s4_158">dose is mandatory. </span>
<span id="t1p_158" class="t s6_158">225,226 </span>
<span id="t1q_158" class="t s5_158">Proton Beam Therapy </span>
<span id="t1r_158" class="t s4_158">At present, proton therapy is the predominant particle therapy under active </span>
<span id="t1s_158" class="t s4_158">clinical investigation in the United States. </span>
<span id="t1t_158" class="t s6_158">227-230 </span>
<span id="t1u_158" class="t s4_158">Proton therapy has been </span>
<span id="t1v_158" class="t s4_158">reported in the treatment of skull base tumors, oropharyngeal cancers, </span>
<span id="t1w_158" class="t s4_158">sinonasal malignancies, adenoid cystic carcinomas, and MMs. </span>
<span id="t1x_158" class="t s6_158">231-239 </span>
<span id="t1y_158" class="t s4_158">Proton therapy has typically been used to treat patients with the most </span>
<span id="t1z_158" class="t s4_158">challenging disease configurations, for which other RT options were not </span>
<span id="t20_158" class="t s4_158">felt to be safe or of any benefit. </span>
<span id="t21_158" class="t s6_158">234,240,241 </span>
<span id="t22_158" class="t s4_158">Proton therapy has also been </span>
<span id="t23_158" class="t s4_158">proposed for children and young adults where a reduced exposure to low- </span>
<span id="t24_158" class="t s4_158">level falloff radiation dose is an appealing feature. </span>
<span id="t25_158" class="t s4_158">Data supporting the use of proton beam therapy (PBT) come mainly from </span>
<span id="t26_158" class="t s4_158">nonrandomized institutional reports and a small number of systematic </span>
<span id="t27_158" class="t s4_158">reviews. A systematic review and meta-analysis of non-comparative </span>
<span id="t28_158" class="t s4_158">observation studies concluded that patients with malignant diseases of the </span>
<span id="t29_158" class="t s4_158">nasal cavity and paranasal sinuses who received proton therapy appeared </span>
<span id="t2a_158" class="t s4_158">to have better outcomes than those receiving photon therapy. </span>
<span id="t2b_158" class="t s6_158">242 </span>
<span id="t2c_158" class="t s4_158">A review </span>
<span id="t2d_158" class="t s4_158">of proton therapy in patients with H&amp;N cancers included 14 retrospective </span>
<span id="t2e_158" class="t s4_158">reviews and four prospective nonrandomized studies. </span>
<span id="t2f_158" class="t s6_158">228 </span>
<span id="t2g_158" class="t s4_158">The 2- to 5-year </span>
<span id="t2h_158" class="t s4_158">local control rates were as low as 17.5% for T4 or recurrent paranasal </span>
<span id="t2i_158" class="t s4_158">sinus cancers and as high as 95% for other tumor types. </span>
<span id="t2j_158" class="t s4_158">In institutional series, the reported outcomes for proton therapy have </span>
<span id="t2k_158" class="t s4_158">included good locoregional control, freedom from distant metastasis, and </span>
<span id="t2l_158" class="t s4_158">acceptable toxicity. </span>
<span id="t2m_158" class="t s6_158">228,236,239,243-246 </span>
<span id="t2n_158" class="t s4_158">PBT may be associated with even </span>
<span id="t2o_158" class="t s4_158">greater normal tissue sparing without sacrificing target coverage, which is </span>
<span id="t2p_158" class="t s4_158">hypothesized to be associated with reduced toxicity compared to IMRT. </span>
<span id="t2q_158" class="t s6_158">243 </span>
<span id="t2r_158" class="t s4_158">This may be a particular advantage in cases of reirradiation. </span>
<span id="t2s_158" class="t s6_158">247 </span>
<span id="t2t_158" class="t s7_158">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
